Skip to main content
. Author manuscript; available in PMC: 2024 Apr 4.
Published in final edited form as: Curr Oncol Rep. 2023 Jan 27;25(3):189–199. doi: 10.1007/s11912-023-01361-0

Figure 1.

Figure 1

The stimulator of interferon genes (STING) pathway is activated though cytosolic DNA sensors including cyclic GMP-AMP synthase (cGAS). Activation leads to the production of Type I interferons. STING agonists may synergize with various other forms of immunotherapy including CAR-T cells, CPIs, BiTEs, and radiotherapy to improve anti-tumor activity.